RESUMEN
To date, there has been only one in vitro study of the relationship between neuropeptide EI (NEI) and the hypothalamic-pituitary-thyroid (HPT) axis. To investigate the possible relationship between NEI and the HPT axis, we developed a rat model of hypothyroidism and hyperthyroidism that allows us to determine whether NEI content is altered in selected brain areas after treatment, as well as whether such alterations are related to the time of day. Hypothyroidism and hyperthyroidism, induced in male rats, with 6-propyl-1-thiouracil and l-thyroxine, respectively, were confirmed by determination of triiodothyronine, total thyroxine, and thyrotropin levels. All groups were studied at the morning and the afternoon. In rats with hypothyroidism, NEI concentration, evaluated on postinduction days 7 and 24, was unchanged or slightly elevated on day 7 but was decreased on day 24. In rats with hyperthyroidism, NEI content, which was evaluated after 4 days of l-thyroxine administration, was slightly elevated, principally in the preoptic area in the morning and in the median eminence-arcuate nucleus and pineal gland in the afternoon, the morning and afternoon NEI contents being similar in the controls. These results provide the bases to pursue the study of the interaction between NEI and the HPT axis.
Asunto(s)
Encéfalo/metabolismo , Hipertiroidismo/metabolismo , Hipotiroidismo/metabolismo , Eminencia Media/metabolismo , Oligopéptidos/biosíntesis , Hipófisis/metabolismo , Glándula Tiroides/metabolismo , Animales , Encéfalo/efectos de los fármacos , Hipertiroidismo/inducido químicamente , Hipertiroidismo/fisiopatología , Hipotiroidismo/inducido químicamente , Hipotiroidismo/fisiopatología , Masculino , Eminencia Media/efectos de los fármacos , Hipófisis/efectos de los fármacos , Propiltiouracilo/efectos adversos , ARN Mensajero , Ratas , Ratas Sprague-Dawley , Glándula Tiroides/efectos de los fármacos , Tirotropina/biosíntesis , Tiroxina/efectos adversos , Triyodotironina/biosíntesisRESUMEN
In this study, we investigated: (a) the effect of melanocyte concentrating hormone (MCH) and neuropeptide glutamine (E)-isoleusine-(I) (NEI) on IP(3) production on an "in vitro" model using slices containing caudate putamen (CP) and accumbens nuclei (ACC); and (b) the interaction between these peptides and with alpha-melanocyte-stimulating-hormone (alpha-MSH) on the production of this second messenger. Only MCH at the highest dose studied (3.6 microM) increased the production of IP(3), whereas at the low concentration (0.6 microM) it did not affect IP(3) levels. NEI and alpha-MSH at both concentrations tested (0.6 and 3.6 microM), did not affect IP(3) production either. However, when NEI or alpha-MSH (at 3.6 microM) were added together with 3.6 microM MCH, the increase in the IP(3) content induced by this last peptide was blocked.
Asunto(s)
Hormonas Hipotalámicas/farmacología , Inositol 1,4,5-Trifosfato/metabolismo , Melaninas/farmacología , Neostriado/efectos de los fármacos , Neostriado/metabolismo , Neuropéptidos/farmacología , Hormonas Hipofisarias/farmacología , alfa-MSH/farmacología , Animales , Interacciones Farmacológicas , Técnicas In Vitro , Masculino , Ratas , Ratas WistarRESUMEN
The neuropeptide (N) glutamic acid (E) isoleucine (I) amide (NEI) injected into the ventral tegmental area (VTA) or intraventricularly (icv) induces excessive grooming behavior (EGB) and motor activity (MA). Here, we studied whether the cholinergic system is involved in the NEI-induced behavior. The present results demonstrate that atropine, a general muscarinic antagonist, injected icv previous to NEI, suppresses the behavior provoked by icv injections of the peptide, whereas the prior icv injection of dyhidro-beta-erythroidine, a general nicotinic antagonist, did not affect the EGB and MA induced by the peptide. From the experimental evidence, it is suggested that NEI may act specifically on a cholinergic afferent to dopaminergic cells. Also, the results appear to indicate that a neural target, different from the dopamine system, may be activated by the peptide to elicit behavioral changes, such as EGB.